Hellström K E, Hellström I
Ann N Y Acad Sci. 1976;276:176-87. doi: 10.1111/j.1749-6632.1976.tb41645.x.
Lymphocyte mediated immune reactions play a major role in the immunological defense against antigenic tumor cells. Serum factors (antigens, antigen-antibody complexes) can thwart these reactions, perhaps by interfering with a lymphocyte "activation" process. Blocking factors can be eluted from lymphoid cells harvested from tumor-bearing animals. One way of increasing cell-mediated reactivity to tumor antigens appears to be to sensitize (or "activate") lymphocytes against tumor antigens in vitro. Another way may be to inoculate animals with sera containing lymphocyte-dependent and unblocking antibodies. Preliminary evidence is presented that inoculation of such sera from rabbits immunized with mouse embryonie cells and extensively absorbed may delay the appearance of primary, methyleholanthrene-induced sarcomas in BALB/c mice; the mechanisms responsible for this delay remain unknown.
淋巴细胞介导的免疫反应在针对抗原性肿瘤细胞的免疫防御中起主要作用。血清因子(抗原、抗原 - 抗体复合物)可能会干扰淋巴细胞“激活”过程,从而阻碍这些反应。阻断因子可从荷瘤动物收获的淋巴细胞中洗脱出来。增强细胞介导的对肿瘤抗原反应性的一种方法似乎是在体外使淋巴细胞对肿瘤抗原致敏(或“激活”)。另一种方法可能是给动物接种含有淋巴细胞依赖性和非阻断性抗体的血清。有初步证据表明,用小鼠胚胎细胞免疫并经过大量吸收的兔血清进行接种,可能会延迟BALB/c小鼠原发性甲基胆蒽诱导肉瘤的出现;导致这种延迟的机制尚不清楚。